Could cutting immune drugs save kidney transplants during severe infections?

NCT ID NCT06881927

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether reducing immunosuppressive drugs (along with giving a steroid) helps kidney transplant patients recover from septic shock or severe breathing failure in the ICU. About 212 adults whose transplant was at least 3 months ago will be randomly assigned to either lower their usual immune drugs or continue them. The goal is to see if this approach improves organ function without raising the risk of rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydrocortisone hemisuccinate (a steroid) and reduction of usual immunosuppressive drugs
What this could lead to
If it works, this could lead to a safer way to manage immunosuppression during critical illness, improving recovery and reducing organ damage in kidney transplant patients.
What could go wrong
This is a Phase 4 trial with 212 participants, so results are not yet proven. Reducing immunosuppression may increase the risk of graft rejection, and the steroid itself has side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.